Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Celldex Therapeutics (CLDX)

Celldex Therapeutics (CLDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,002,971
  • Shares Outstanding, K 66,566
  • Annual Sales, $ 7,020 K
  • Annual Income, $ -157,860 K
  • EBIT $ -235 M
  • EBITDA $ -247 M
  • 60-Month Beta 1.24
  • Price/Sales 1,320.12
  • Price/Cash Flow N/A
  • Price/Book 3.42

Options Overview Details

View History
  • Implied Volatility 58.86% (+0.15%)
  • Historical Volatility 78.47%
  • IV Percentile 1%
  • IV Rank 3.51%
  • IV High 155.78% on 11/10/25
  • IV Low 55.34% on 04/22/25
  • Expected Move (DTE 20) 3.11 (10.34%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 55
  • Volume Avg (30-Day) 585
  • Put/Call OI Ratio 1.08
  • Today's Open Interest 2,864
  • Open Int (30-Day) 3,862
  • Expected Range 26.98 to 33.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -1.25
  • Number of Estimates 4
  • High Estimate -1.22
  • Low Estimate -1.27
  • Prior Year -0.81
  • Growth Rate Est. (year over year) -54.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.33 +34.75%
on 02/06/26
31.31 -3.90%
on 02/26/26
+3.86 (+14.72%)
since 01/27/26
3-Month
22.33 +34.75%
on 02/06/26
31.31 -3.90%
on 02/26/26
+3.30 (+12.32%)
since 11/26/25
52-Week
14.40 +108.96%
on 04/09/25
31.31 -3.90%
on 02/26/26
+9.78 (+48.15%)
since 02/27/25

Most Recent Stories

More News
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile...

- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved quality...

CLDX : 30.09 (-1.80%)
Celldex: Q4 Earnings Snapshot

Celldex: Q4 Earnings Snapshot

CLDX : 30.09 (-1.80%)
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned...

CLDX : 30.09 (-1.80%)
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria

Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU Topline data expected Q4 2026 BLA submission planned for 2027 HAMPTON, N.J.,...

CLDX : 30.09 (-1.80%)
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile

HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous...

CLDX : 30.09 (-1.80%)
Celldex to Present at Upcoming Investor Conferences

HAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim...

CLDX : 30.09 (-1.80%)
2 ‘Strong Buy’ Growth Stocks With Upside of Around 200%

These growth stocks have the potential to dramatically outperform if you are willing to bear the risks.

VKTX : 33.84 (+2.64%)
CLDX : 30.09 (-1.80%)
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism

No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient life Barzolvolimab is the only drug in development to demonstrate clinical benefit...

CLDX : 30.09 (-1.80%)
Celldex: Q3 Earnings Snapshot

Celldex: Q3 Earnings Snapshot

CLDX : 30.09 (-1.80%)
Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained...

CLDX : 30.09 (-1.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 70%. The market has dropped from overbought territory. Beware of a potential mean reversion.

See More Share

Business Summary

CELLDEX THERAPEUTICS is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal...

See More

Key Turning Points

3rd Resistance Point 31.59
2nd Resistance Point 31.02
1st Resistance Point 30.56
Last Price 30.09
1st Support Level 29.52
2nd Support Level 28.96
3rd Support Level 28.49

See More

52-Week High 31.31
Last Price 30.09
Fibonacci 61.8% 24.85
Fibonacci 50% 22.85
Fibonacci 38.2% 20.86
52-Week Low 14.40

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar